Introduction
Osteoporosis is an important health problem. As the lifetime risk for fragility fractures is only 15% in men compared with 40% in women; men are protected against osteoporosis and osteoporotic fractures. Therefore, the understanding of the male skeletal physiology may lead to new modalities for treatment and prevention of osteoporosis. In this respect, the key role of gonadal steroidsboth androgens and estrogens -in male bone metabolism received a lot of attention during the last decade. This was the focus of an excellent review in Current Opinion in Endocrinology, Diabetes & Obesity by Leder in 2007 [1 ] . Some more recent important observations with respect to gonadal steroid action and male bone metabolism will be highlighted in this review article.
The role of androgens on male bone metabolism is twofold. First, androgens stimulate bone formation during puberty. Second, androgens prevent bone resorption during and after puberty. The first part of this review will focus on androgen action on the growing skeleton during puberty, whereas in the second part the role of androgens after puberty will be discussed.
Androgens and bone formation
Androgens can be converted into estrogens by the P450 aromatase enzyme and may therefore act as a precursor hormone for estrogens. Indeed, not only androgen but also estrogen metabolism and action are essential for male bone maturation and homeostasis, as described by several studies last year [2] [3] [4] . Most of our recent knowledge of the role of estrogens on male skeletal physiology has been derived from experiments of nature. In this context, seven men suffering from estrogen deficiency due to an inactivating mutation of the aromatase enzyme have been reported, with low areal bone mineral density (BMD) as measured by dual-energy X-ray absorptiometry. Furthermore, Rochira et al.
[5 ] described in more detail the skeletal effects of testosterone alone as compared with testosterone and estradiol in an adult aromatase deficient man with concomitant mild hypogonadism during more than 7 years of follow-up. Their data showed that only the combination of testosterone and estradiol increased areal BMD to a greater extent than testosterone alone. This increased areal BMD was paralleled by an increase of the cortical thickness at the radius and tibia, as measured by peripheral quantitative
Purpose of review
The present review will focus on the most important recent findings with respect to skeletal androgen action. Many studies have indicated that part of the androgen action may be related to the conversion of androgens into estrogens. Therefore, some of the most recent findings of skeletal estrogen action relevant for male skeletal physiology will also be discussed.
Recent findings
Androgens and estrogens stimulate bone formation and inhibit bone resorption. Sex steroids may interact with different receptors, target cells and other bone anabolic pathways. Androgen receptor and estrogen receptor signalling appear to be important for male bone formation during growth. Sex steroid signalling may involve genomic and nongenomic pathways, interaction with mechanical loading, the growth hormone/ insulin-like growth factor-I axis and/or other bone anabolic pathways. Estrogen receptor a in osteoclasts appears to regulate bone resorption in women but not men, whereas androgen receptor signalling in osteoblasts may only partly regulate bone resorption in males.
Summary
The latest developments indicate that androgens and estrogens are important for male bone metabolism and homeostasis and therefore selective estrogen receptor a and androgen receptor signalling remain interesting drug targets for the stimulation of bone formation and male skeletal integrity.
computed tomography (pQCT). This observation indicates that testosterone increases bone formation only in the presence of sufficient estrogen administration. A similar increase in cortical thickness and width following estrogen administration has been reported by our group in a much younger aromatase deficient patient [6] . Moreover, previous studies in transgenic mice with estrogen receptor a (ERa) or androgen receptor (AR) disruption have shown that bone formation is reduced in male mice as a result of the inactivation of either one of these receptors [7-9]. These findings indicate that both androgens and estrogens are needed for male skeletal maturation in humans and in rodents. Recent studies have addressed the underlying mechanism of these estrogensignalling pathways resulting in an upregulation of bone formation. It is now clear that ERa and not ERb is involved in the stimulation of bone formation during puberty, at least in male mice [7] . ERa signalling appears to be involved in the bone stimulatory action of mechanical loading as well, one of the most important physiological stimuli for bone formation during growth. Along the same line, Armstrong et al. [10 ] reported that the Wnt/b-catenin signalling is a component of the osteoblastic bone cell early response to mechanical strain and that this pathway seems to require estrogen receptora. This observation is of particular interest because the Wnt/b-catenin signalling pathway may become one of the most promising drug targets for future anabolic therapies. Estrogens are generally considered to have mainly antiresorptive and little or no anabolic skeletal effects. However, more and more recent data suggest that estrogen -or at least components of its a receptorsignalling pathway -may be involved in the stimulation of bone formation. In this context, an interesting report from the Gothenburg Osteoporosis and Obesity Determinants (GOOD) study [11 ] was published last year. According to this study, the interaction between mechanical loading -as determined by the amount of physical activity -and estrogen metabolism may be a determinant of bone mineral accumulation in young men. Lorentzon et al.
[11 ] reported on the role of a polymorphism in the cathecol-O-methyltransferase (COMT) gene, which encodes for the COMT enzyme involved in the degradation of estrogens. A functional polymorphism in the COMT gene (val158met) results in a 60-75% difference in enzyme activity between the Val (high-enzyme activity) and Met (low-enzyme activity) variants. Interestingly, this polymorphism was not only associated with BMD but also with the effects of physical activity on bone density, but only in men with the Met (low) COMT genotype. Furthermore, the H 268 Y polymorphism in the uridine diphosphate glucuronosyltransferase (UGT) 2B7gene, which encodes an enzyme involved in the irreversible glucuronidation of sex steroids and metabolites, is associated with cortical bone size and serum sex steroid levels in young adult men.
Subjects homozygous for the Y allele had higher serum testosterone and larger cortical bone size than subjects homozygous for the H allele [12] .
Estrogen signalling may stimulate bone formation through genomic and/or nongenomic signalling. Kousteni et al. [13 ] showed that direct activation of several cytoplasmatic kinases by ERa following ligand activation might be more anabolic for bone than its interaction with DNA. In their study, this nongenomic estrogen signalling stimulated Wnt/b-catenin signalling as well as bone morphogenetic protein-2 (BMP-2) signalling in osteoblasts. Like Wnt/b-catenin signalling, BMP-2 signalling may be an important bone-forming pathway in osteoblasts [14] . Therefore, nongenomic estrogen signalling could also become an interesting drug target for anabolic therapy, at least when ligands or compounds are found that are able to stimulate only nonreproductive tissues such as bone, without effects on other tissues like breast or uterus. However, the role of nongenomic estrogen signalling on anabolic action remains to be clarified [15] . The question is if and to what extent compounds such as estren (which were initially considered to target cytoplasmatic kinases and not DNA) have selective effects on bone.
An interesting study by Windahl et al. [16 ] identified target cells for the genomic effects of estrogens on bone by using reporter mice with a luciferase gene under the control of estrogen responsive elements (EREs). An estradiol-induced increase in luciferase activity was detected in cortical bone and bone marrow, indicating that bone is a target tissue for the classical genomic ERE-mediated effects of estrogens. More specifically, hypertrophic chondrocytes, megakaryocytes, osteoblasts and lining cells are considered to respond to estrogen by the classical ERE-genomic signalling as they displayed positive luciferase staining, whereas proliferative chondrocytes and most osteocytes did not show luciferase staining.
The extent to which androgens and components of the AR-signalling pathway affect the Wnt/b-catenin signalling or mediate osteoblastic responses to loading remains to be determined, and so does the extent to which such action may be involved in the androgenic stimulation of bone formation. One recent study [17 ] suggested thatat least in vitro -nonaromatizable androgens could stimulate osteoblastic differentiation through interaction with Wnt signalling. Furthermore, Takai et al. [18 ] showed in vitro that the AR stimulates bone sialoprotein gene transcription by targeting the cAMP response element (CRE) and activator protein 1/glucocorticoid response element (AP-1/GRE) in the promoter of the rat BSP gene, a mechanism possibly involved in the bonestimulatory action of androgens.
Besides gonadal steroids, growth hormone (GH) remains one of the most important bone-forming hormones during growth. The interaction between estrogens and the GH/IGF-I axis has been well established [19] . Estrogens may indirectly stimulate the growth spurt and bone formation through interaction with the GH/IGF-I axis, not only in women but also in men. The extent to which androgen and AR signalling interact with the GH/IGF-I axis is less well established. We recently showed that androgens stimulate bone formation in mice even with no functional growth hormone receptor (GHR) [20 ] . GHR activation, however, seems to be the main determinant of radial bone expansion, although GHR signalling and androgens are both necessary to stimulate periosteal growth during puberty. Interestingly, androgens stimulated not only bone but also muscle mass in these mice. However, the question remains to what extent mechanical loading, which was independently associated with the GH and androgen-related changes in body weight and muscle mass, determines the effects of both hormones on bone formation. Transgenic mice with no sexual dimorphism for lean body mass such as obese leptin knockout mice also lack a sexual dimorphic skeletal size, suggesting that the androgen effect on muscle and body composition may be required for the sexual differentiation of bone size -at least in the absence of leptin [21 ] .
Androgens and bone resorption
Androgens as well as estrogens inhibit bone resorption as was most clearly established in orchidectomized animal models and hypogonadal men [7] . Gonadal steroids may directly inhibit osteoclast generation and activity and/or stimulate osteoclastic cell death or, alternatively, positively affect antiresorptive signalling of osteoblastic cells. The Cre/Lox P system is a suitable technique to knockout a target gene in a specific cell group or tissue [22] . This technique of cell selective disruption of the receptor allows the study of to what extent cell activation of gonadal steroid receptors is involved in bone resorption. Over the past year, two such studies were published. In one study, ERa has been selectively ablated in osteoclasts. In female (but not male) mice with osteoclastic ERa disruption, bone resorption was increased in a similar way as in the osteoporotic bone phenotype observed in postmenopausal women [23 ] . This study found that ERa activation in osteoclasts is important for the inhibition of bone resorption in female mice. The same group had previously suggested that disruption of the AR -in contrast to ERa -increased bone resorption in male mice [24] . Furthermore, in their study, estrogen shortened the life span of mature osteoclasts through the induction of the Fas/FasL system, potentially providing an explanation for the osteoprotective function of estrogens as well as selective estrogen receptor modulators (SERMs). However, the direct link between estrogen deficiency and postmenopausal bone loss has been challenged by Sun et al. [25] , who proposed that folliclestimulating hormone (FSH) is directly responsible for bone loss in hypogonadal follicle-stimulating hormone receptor (FSHR) and FSHb null female mice. In contrast, Gao et al. [26] clearly showed that disturbed hormone levels [elevated luteinising hormone (LH) and testosterone] confound the bone phenotype of these mice and that ovariectomy resulted in similar bone loss in FSHR knockout mice compared with controls, indicating that estrogens affect bone homeostasis independently of FSH [27, 28] . The bone phenotype and effects of gonadectomy in male FSHR and FSHb null mice have not been reported (yet).
Although the role of AR-mediated androgen action in male bone development and preservation has been well established, the primary target cell of the AR-mediated antiresorptive effects remains a matter of debate. In male mice with a specific knockout of the AR in osteoblasts, a decrease in trabecular bone volume has been reported at an older age, along with a decrease in trabecular number, suggesting that androgens may act directly on osteoblasts to maintain trabecular bone [29 ] . However, the trabecular bone phenotype of these mice was much less dramatic than the well documented high-bone turnover trabecular osteopenia in mice with global AR disruption, suggesting that other cells such as osteoclasts and osteoclast precursors and/or other target cells may be involved in the regulation of AR-mediated bone resorption.
The well established antiresorptive skeletal effects of AR stimulation in males have stimulated the search for selective androgen receptor modulators (SARMs) that are orally active [30 ,31] . SARMs are nonsteroidal androgens and are characterized by the fact that they are not substrates for aromatase and 5a-reductase [32] . In addition, SARMs act as full agonists in anabolic organs (muscle and bone) but as partial agonists in androgenic tissues (prostate and seminal vesicles). In this context, SARMs may provide an alternative for testosterone replacement as these compounds reproduce the beneficial effects of androgens without adverse effects such as stimulation of the prostate. Preclinical studies [33, 34] already showed promising protective effects on bone and muscle. Further development and clinical testing of these compounds is needed, but will provide a significant therapeutic advantage for androgen replacement therapy in the treatment of hypogonadism, osteoporosis and sarcopenia. Along the same line, the effects of testosterone on bone and muscle are still maintained when a 5a-reductase inhibitor is administered simultaneously, and thus testosterone action on bone and muscle can be separated from its action on the prostate [35 ] . Also in humans, it has been shown that dihydrotestosterone (DHT) is not essential for the beneficial effect of testosterone on BMD in men [36, 37] . Therefore, testosterone administration with concomitant inhibition of its 5a reduction may provide a testable approach for reversing sarcopenia and osteopenia in older hypogonadal men. Although androgens are clearly important to prevent osteoporosis in hypogonadal men, the role of the relatively mild decline of androgens to maintain skeletal integrity in the elderly is less well established. In a prospective study [38 ] in men, no relation between sex steroids and nonvertebral fractures was found. Although a weak inverse relationship was seen with sex hormone binding globulin (SHBG), which disappeared after adjustment for BMD. However, fractures were not assessed in this study. There is a need for prospective studies of the effect of age-related changes of gonadal steroid functions on fracture rates. Such strategy is relevant because both sexes show a progressive age-related loss of BMD and strength [39 ] . This loss appears to be associated with a decline in bone formation with increased osteoblast and osteocyte apoptosis, increased reactive oxygen species levels and decreased defence against oxidative stress. The same changes in oxidative stress have been reproduced by gonadectomy in males and reversed by androgens. Therefore, not only osteoclasts and osteoblasts, but also osteocytes may become a cell target of androgen action in the ageing male skeleton.
Conclusion
It has now been well established that androgens and estrogens are both important for bone formation and resorption, and their respective contribution to male skeletal homeostasis has been the focus of excellent basic and clinical research during the last year. Androgens through AR activation and estrogens through ERa activation are both required for optimal stimulation of bone formation in males as demonstrated by many studies in mice and men. Their action may be either direct through their respective receptors present in osteoblasts followed by genomic or nongenomic signalling or indirect in response to mechanical loading, modulation of the Wnt/b catenin signalling or interaction with the GH/IGF-I axis. Beside their bone-anabolic actions, androgens and estrogens both exert antiresorptive effects. Although an important antiresorptive role has been attributed to ERa in female osteoclasts, the main target cell for AR-mediated antiresorptive action in males remains to be determined. The search for compounds that selectively stimulate bone and muscle but not other androgenic tissues looks promising and confers a major advantage not only to the improvement of treatment modalities for osteoporosis and sarcopenia but also for the elucidation of the molecular mechanism of AR action in bone cells. As the underlying mechanisms of sex steroids on bone appear extremely complex, future studies must focus on the understanding of different sex steroid receptor signalling pathways and their interaction as a potential drug target for anabolic and/or antiresorptive therapy.
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